Xeris Biopharma Holdings, Inc./$XERS

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Ticker

$XERS
Primary listing

Industry

Pharmaceuticals

Employees

394

ISIN

US98422E1038

XERS Metrics

BasicAdvanced
$734M
-
-$0.30
0.91
-

Bulls say / Bears say

Xeris Biopharma reported a record first quarter in 2025, with total revenue reaching $60.1 million, a 48% increase over the same period in 2024, indicating strong product demand and effective market penetration. (xerispharma.com)
The company achieved a positive adjusted EBITDA of $4.4 million in Q1 2025, marking a significant turnaround from a loss of $4.1 million in Q1 2024, reflecting improved operational efficiency and financial health. (xerispharma.com)
Xeris entered into a worldwide license agreement for its XeriJect® formulation of teprotumumab, potentially expanding its product portfolio and opening new revenue streams. (xerispharma.com)
Despite revenue growth, Xeris reported a net loss of $9.2 million in Q1 2025, indicating ongoing challenges in achieving profitability. (xerispharma.com)
The company's total liabilities increased by 10% from 2023 to 2024, reaching $329 million, which may raise concerns about its debt levels and financial stability. (siriusinvestors.com)
Xeris's operating loss widened from $4.9 million in Q3 2023 to $12.9 million in Q3 2024, suggesting escalating operational costs that could impact future profitability. (dcf-fm)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XERS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs